NCT00281632View on ClinicalTrials.gov

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

October 31, 2010

Conditions
Peritoneal CancerOvarian CancerNeoplasms, OvarianFallopian Tube Cancer
Interventions
DRUG

GW786034

800 mg GW786034 administered orally on a daily basis.

Trial Locations (10)

2031

GSK Investigational Site, Randwick

3084

GSK Investigational Site, Melbourne

4029

GSK Investigational Site, Herston

30342

GSK Investigational Site, Atlanta

75246

GSK Investigational Site, Dallas

76022

GSK Investigational Site, Bedford

76104

GSK Investigational Site, Fort Worth

78731

GSK Investigational Site, Austin

119074

GSK Investigational Site, Singapore

229899

GSK Investigational Site, Singapore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY